Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease. Issue 6 (23rd December 2019)

• Record Type: Journal Article
• Authors: van Geyzel, Lisa; Arigliani, Michele; Inusa, Baba; Singh, Bethany; Kozlowska, Wanda; Chakravorty, Subarna; Bossley, Cara J; Ruiz, Gary; Rees, David; Gupta, Atul
• Is Part Of: Archives of disease in childhood. Volume 105:Issue 6(2020)
• Page Start: 575
• Page End: 579
• Publication Date: 2019-12-23
• Subjects: haematology -- sickle cell disease -- hydroxyurea -- hypoxaemia; Children -- Diseases -- Periodicals; Infants -- Diseases -- Periodicals; 618.920005
• DOI: 10.1136/archdischild-2019-317862
• Languages: English
• ISSNs: 0003-9888

Abstract

Abstract : Introduction: Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. It is associated with lifelong morbidity and reduced life expectancy. Hydroxyurea (HU) has been shown to reduce the frequency and severity of vaso-occlusive episodes in SCD. Hypoxaemia and intermittent nocturnal oxygen desaturations occur frequently in children with SCD and contribute to the associated morbidity, including risk of cerebrovascular disease. Objective: To evaluate the effect of HU on oxygen saturation (SpO2 ) overnight and on daytime SpO2 spot checks in children with SCD. Methods: A retrospective review of children with SCD and respiratory problems who attended two UK tertiary sickle respiratory clinics and were treated with HU. Longitudinal data were collected from 2 years prior and up to 3 years after the commencement of HU. Results: Forty-three children, 23 males (53%) with a median age of 9 (range 1.8–18) years were included. In the 21 children who had comparable sleep studies before and after starting HU, mean SpO2 was higher (95.2% from 93.5%, p=0.01) and nadir SpO2 was higher (87.2% from 84.3%, p=0.009) when taking HU. In 32 of the children, spot daytime oxygen saturations were also higher (96.3% from 93.5%, p=0.001). Conclusion: Children with SCD had higher oxygen saturation overnight and on daytime spot checks after starting HU. These data suggest HU may be helpful for treating persistent hypoxaemia in children with SCD pending more evidence from a randomised clinical trial.